Who is sponsoring NCT03346226?

NCT03346226 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT03346226?

Interventions in NCT03346226: Dexmedetomidine Hydrochloride, Propofol.

What condition does NCT03346226 study?

NCT03346226 studies Delirium in Old Age.

Is NCT03346226 still recruiting?

NCT03346226 is currently status unknown. Last updated 13 December 2017.

Last reviewed 2017-12-13 · How we verify

NCT03346226

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

How Different Sedatives Affect Hip Fracture Patient's Postoperative Delirium

Status unknown Phase 4 Last updated 13 December 2017

What this trial tests

Phase 4 trial testing Dexmedetomidine Hydrochloride in Delirium in Old Age in 1,000 participants. Status unknown.

Timeline

1 January 2018

Primary endpoint
30 December 2018

30 June 2019

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	1,000
Start date	1 January 2018
Primary completion	30 December 2018
Estimated completion	30 June 2019

Drugs / interventions tested

Dexmedetomidine Hydrochloride — full drug profile →
Propofol (Propofol) — full drug profile →

Conditions studied

Delirium in Old Age — all drugs for Delirium in Old Age →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 65 to 90, any sex, with Delirium in Old Age. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

the hypothesis is that Dexmedetomidine seems to decrease incidence of post-operative delirium . one possible mechanism is that Dex have a minor influence on cognition, since it has no effect on GABA receptor，another is that Dex could induce a sleep similar to natural sleep, thereby decreasing sleep deprivation and circadian rhythm disorder in post-operative patients. In this study , investigators devise the two different sedatives(Dexmedetomidine and Propofol)'influence on postoperative delirium in hip fracture elderly participants under spinal anesthesia

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dexmedetomidine Hydrochloride

Trials testing the same drug.

NCT05793060 — Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Intermediate Cervical Plexus Block · Phase 4 · recruiting
NCT06575530 — Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients · Phase 4 · recruiting
NCT05264077 — Efficacy of Dexmedetomidine vs Midazolam for Early Extubation in Critically Ill Agitated Patients Undergoing Weaning · EARLY_PHASE1 · not yet recruiting
NCT06502002 — Dexmedetomidine Infusion and Postoperative Lung Aeration After Thoracic Surgery · NA · completed
NCT06417125 — Intranasal Dexmedetomidine Versus Oral Midazolam Premedication for Postoperative Negative Behavior Changes in Children · Phase 4 · completed

Other recruiting trials for Delirium in Old Age

Currently open trials in the same condition.

NCT06721819 — The SCOPE Trial: Sleep, Cognition, and Pain Bundle vs. ERAS-cardiac for Postoperative Delirium · Phase 3 · recruiting
NCT06216483 — Using EMR Data and AI to Develop a Passive Digital Marker to Predict Postoperative Delirium · NA · active not recruiting
NCT06100029 — The Effect of Lavender Essential Oil for Delirium in Elderly Intensive Care Unit Patients: Study Protocol · NA · recruiting
NCT05242419 — A Study of Huperzine A Injection in Reducing Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Surgery · NA · recruiting

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03346226 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 13 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03346226.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing